US Bancorp DE Acquires 7,406 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

US Bancorp DE boosted its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 61.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,366 shares of the biotechnology company’s stock after buying an additional 7,406 shares during the period. US Bancorp DE’s holdings in Aurinia Pharmaceuticals were worth $174,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its position in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 6,174 shares in the last quarter. FMR LLC raised its position in Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 3,919 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $108,000. Atria Wealth Solutions Inc. purchased a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $135,000. Finally, BNP Paribas Financial Markets raised its position in Aurinia Pharmaceuticals by 172.9% during the third quarter. BNP Paribas Financial Markets now owns 32,078 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 20,324 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Insider Transactions at Aurinia Pharmaceuticals

In other news, CFO Joseph M. Miller sold 61,859 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $494,872.00. Following the transaction, the chief financial officer now owns 633,515 shares in the company, valued at approximately $5,068,120. The trade was a 8.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Greg Keenan sold 12,239 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the transaction, the insider now owns 161,789 shares in the company, valued at approximately $1,294,312. This represents a 7.03 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 343,898 shares of company stock worth $2,753,094. Company insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Aurinia Pharmaceuticals Stock Up 0.6 %

AUPH opened at $8.16 on Friday. The company has a market cap of $1.12 billion, a P/E ratio of -54.40 and a beta of 1.26. The business’s 50-day moving average price is $8.01 and its 200-day moving average price is $7.93. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $10.67.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.